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Background/aim: JAK2V617F mutation is expressed in almost all polycthemia vera (PV), 55% of essential thrombocythemia (ET),
and 65% of primary myelofibrosis (PMF) patients. Studies investigating phenotypic effects of JAK2V617F mutation on Philadelphianegative myeloproliferative neoplasms (Ph-negative MPNs) have reported controversial results. This study aims to determine the impact
of JAK2V617F mutation on clinical phenotype and outcome in Ph-negative MPNs.
Materials and methods: Clinical correlates and long-term prognostic relevance of the JAK2V617F mutation were analyzed in 410 Phnegative MPNs-170 ET, 135 PV, 105 PMF- from two institutions and followed for a mean of 76.7 months (SD 62.1) (mean 87 months
(SD 67.8), 70.4 months (SD 56.4), 68 months (SD 57.4), respectively for ET, PV, and PMF). Two hundred and twenty-eight patients were
genotyped for JAK2V617F mutation using the JAK2 Ipsogen MutaScreen assay, which involves allele-specific polymerase chain reaction
(PCR), and 182 patients were genotyped using melting curve analysis.
Results: In PV patients, JAK2V617F mutation was associated with higher rate in females, lower hemoglobin (Hgb) level, higher
leukocyte and platelet count and higher prevalence of thrombosis (p = 0.008, p = 0.018, p = 0.001, p = 0.001, and p = 0.035, respectively).
In ET patients, JAK2V617F mutation was associated with higher Hgb and hematocrit (Hct) levels and lower platelet count (p = 0.001, p
= 0.001, and p = 0.001, respectively). JAK2V617F-negative ET patients showed a trend towards higher rate of leukemic transformation
(p = 0.061). JAK2V617F mutation-positive PMF patients had higher leukocyte count, greater spleen size and showed a trend towards
higher Hgb level (p = 0.019, p = 0.042, and p = 0.056, respectively). Among PMF patients with JAK2V617F mutation, the rate of female
patients was lower (p = 0.001). Overall survival (OS) in Dynamic International Prognostic Scoring System (DIPSS) - plus high risk
PMF patients was shorter compared to the other risk groups (p = 0.001). Leukemia-free survival (LFS) was shorter in DIPSS - plus high
risk PMF patients than the other risk groups (p = 0.005). In the entire cohort of Ph-negative MPN patients, JAK2V617F mutation was
associated with higher leukocyte count, higher Hgb and Hct levels and lower platelet count, higher frequency of phlebotomies, a trend
towards older age, a trend towards greater spleen size, a trend towards a higher prevalence of risk factors for cardiovascular diseases and
thrombosis (p = 0.001, p = 0.005, p = 0.001, p = 0.003, p = 0.004, p =0.052, p = 0.056, p = 0.052, and p = 0.059, respectively).
Conclusion: In our study population, it was demonstrated that the presence of JAK2V617F mutation in ET patients was associated
with PV-like phenotype. Our study also showed that the presence of the JAK2V617F mutation was associated with increased risk
of thrombotic complications. Our results suggest that JAK2V617F mutation is associated with a more pronounced myeloproliferative
phenotype in PMF patients. In a large number of Ph-negative MPN patients, our findings support that JAK2V617F mutation is associated
with a more aggressive phenotype.
Key words: JAK2V617F mutation, polycthemia vera, essential thrombocythemia, primary myelofibrosis, Philadelphia–negative
myeloproliferative neoplasms

1. Introduction
The World Health Organization (WHO) classification
system for hematopoietic tumors was last updated in
2016. Myeloproliferative neoplasms (MPNs) are one of the
several myeloid malignancies. The Philadelphia-negative
(Ph-negative) MPNs are a heterogeneous group of diseases

originating at the level of the pluripotent hematopoietic
stem cell and include three major diseases: polycthemia
vera (PV), essential thrombocythemia (ET) and primary
myelofibrosis (PMF) [1]. PV and ET are characterized by
clonal erythrocytosis and thrombocytosis, respectively.
Other disease features include leukocytosis, splenomegaly,
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thrombosis, bleeding, microcirculatory symptoms, pruritus
and risk of progression to myelofibrosis or acute myeloid
leukemia [2]. Characteristic features of PMF are bone
marrow reticulin/collagen fibrosis, increased inflammatory
cytokine expression, anemia, hepatosplenomegaly,
extramedullary hematopoiesis, constitutional symptoms,
leukemic progression, and shorter life expectancy [3]. The
discovery that almost all PV patients, 55% of ET and 65%
of PMF patients express a mutation in the Janus Kinase
2 gene (JAK2V617F) provided a molecular basis for the
unregulated hematopoiesis typical of these disorders [2].
Several studies have investigated the impact of JAK2V617F
mutation on clinical phenotype in PV, ET, PMF, and entire
cohort of Ph-negative MPNs [4-11]. In the same group of
patients, the impact of JAK2V617F mutation on overall
survival (OS) and leukemia-free survival (LFS) has been
the subject of several studies, the results of which were
controversial [8,12-17]. This study investigated the clinical
and laboratory correlates in 410 patients diagnosed with
Ph-negative MPNs - 170 ET, 135 PV, 105 PMF - according
to the presence of JAK2V617F mutation. Furthermore, in
this large patient series of Ph-negative MPNs with long
term follow-up, we evaluated the prognostic relevance of
the JAK2V617F mutation.
2. Materials and methods
We extracted from our database 410 consecutive Phnegative MPN patients - 170 ET, 135 PV, 105 PMF diagnosed between 1995 and 2019. Of the whole study
group, 257 and 153 patients were under follow-up at the
Division of Hematology of Istanbul University Istanbul
Medical Faculty and Hematology Clinic of University of
Health Sciences Bakırköy Dr. Sadi Konuk Training and
Research Hospital, respectively. All patients fullfilled the
2016 WHO diagnostic criteria for MPNs [18]. Causes
of secondary polycythemia, reactive thrombocytosis,
familial thrombocytosis, accompanying comorbid disease
related anemia, infection related leukocytosis, bone
marrow fibrosis other than MF were excluded. Informed
consent was obtained from all participants. The study was
approved by the local ethics committee and was conducted
in accordance with the Declaration of Helsinki. Clinical
history, blood count, lactate dehydrogenase (LDH)
level, spleen size, presence of cardiovascular risk factors
(cigarette, hypertension, diabetes, and dyslipidemia),
history of phlebotomy, thrombotic or hemorrhagic
complications, death and leukemic transformation were
recorded. Dynamic International Prognostic Scoring
System (DIPSS)-plus was used for risk stratification in
PMF [19]. Unfavorable karyotypes in PMF were described
as complex karyotype or one or two abnormalities that
include +8, -7/7q-, i(17q), -5/5q-, inv(3), 12p-, or 11q23
rearrangement [20]. In 228 of 410 patients, real-time

semiquantitative polymerase chain reaction (PCR) with
JAK2 MutaScreen assay (Ipsogen, Luminy Biotech,
Marseille, France) was used to screen JAK2V617F mutation
and the mutant allele burden [21]. In the remaing 182
patients, JAK2V617F mutation was detected by fluorescent
resonance energy transfer (FFET) probes and Light Cycler
techniques by using Melting Curve analysis [22].
3. Statistical analysis
SPSS version 21 (IBM, Armonk, NY, USA) was used
for statistical calculations. Numerical variables were
summarized by mean (SD). One-sample Kolmogorov–
Smirnov test was performed to assess the distribution of
the variables in order to use a parametric or nonparametric
test. The chi-square statistics were performed to compare
categorical variables among the different patient groups
categorized according to the JAK2V617F mutational
status. The Student t-test and Mann–Whitney U test
were used to compare the normally and nonnormally
distributed continuous data between two groups,
respectively. A p-value of less than 0.05 was regarded as
statistically significant; all tests were two-tailed. Seperate
OS curves were constructed by Kaplan–Meier method for
ET, PV, PMF patients and the whole cohort of Ph-negative
MPN patients. Also, Kaplan–Meier estimation was used to
plot LFS curves for Ph-negative MPN patients and PMF
patients.
4. Results
In a total of 410 Ph-negative MPN patients (170 ET, 135
PV, 105 PMF), the frequency of JAK2V617F mutation was
72.7% (n = 298). The frequency of JAK2V617F mutation
in ET, PV, and PMF patients was 63.5%, 81.5%, and 76.2%,
respectively. In the follow-up of the total cohort of 410
patients, 128 patients (31.2%) underwent phlebotomies.
Venous thrombosis was detected in 15% (n = 26), 10% (n
= 11) and 15.5% (n = 21) of ET, PV and PMF patients,
respectively. Of the 26 ET patients with venous thrombosis,
12 presented with abdominal vein thrombosis, 7 with
cerebral vein thrombosis, 4 with deep vein thrombosis
(DVT), 2 with pulmonary embolism (PE) and 1 patient
presented with concomitant DVT and abdominal
vein thrombosis. Of the 11 PMF patients with venous
thrombosis, 9 presented with abdominal vein thrombosis,1
with DVT and 1 patient presented with PE. Of the 21
PV patients with venous thrombosis, 11 presented with
abdominal vein thrombosis, 6 with DVT, 2 with cerebral
vein thrombosis, 1 with PE and 1 patient presented with
concomitant DVT and cerebral vein thrombosis. Arterial
thrombosis was detected in 22% (n = 37), 12% (n = 13) and
24% (n = 32) of ET, PV, and PMF patients, respectively. Of
the 37 ET patients with arterial thrombosis, 13 presented
with coronary artery thrombosis, 12 with cerebral artery
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thrombosis, 5 with peripheral artery thrombosis, 4 with
concomitant coronary and cerebral artery thrombosis, 1
with concomitant renal and coronary artery thrombosis, 1
with concomitant cerebral and peripheral artery thrombosis
and 1 patient presented with concomitant coronary and
peripheral artery thrombosis. Of the 13 PMF patients
with arterial thrombosis, 7 presented with coronary artery
thrombosis, 3 with peripheral artery thrombosis, 2 with
concomitant coronary and cerebral artery thrombosis and
1 patient presented with cerebral artery thrombosis. Of
the 32 PV patients with arterial thrombosis, 18 presented
with coronary artery thrombosis, 11 with cerebral artery
thrombosis, 1 with peripheral artery thrombosis, 1 with
concomitant coronary and cerebral artery thrombosis and
1 patient presented with concomitant cerebral and renal
artery thrombosis. Bleeding was observed in 12.7% (n =
52) of the whole study population. The source of bleeding
was gastrointestinal tract, oral mucosa, cutaneous,
intracranial, alveolar, ocular, concomitant cutaneous, oral
mucosa, and gastrointestinal tract in 5.6% (n = 23), 3.2%
(n = 13), 2%(n = 8), 1% (n = 4), 0.5% (n = 2), 0.2% (n = 1),
0.2% (n = 1), respectively of the 52 bleeding patients. Of the
17 ET patients with bleeding, the source of bleeding was
gastrointestinal tract, oral mucosa, cutaneous, ocular and
intracranial in 8, 4, 3, 1, and 1 patient, respectively. Of the
21 PMF patients with bleeding, the source of bleeding was
gastrointestinal tract, oral mucosa, cutaneous, intracranial,
concomitant cutaneous, oral mucosa and gastrointestinal
tract and alveolar in 9, 6, 2, 2, 1, and 1 patient, respectively.
The cause of mortality in PV patients were sudden cardiac
death (SCD) (n = 8) and leukemic transformation (n =
2). In ET patients, the cause of mortality was respiratory

failure (n = 3), liver failure (n = 1), SCD (n = 12) and
leukemic transformation (n = 2). In PMF patients, the
cause of mortality was respiratory failure (n = 9), SCD (n
= 18) and leukemic transformation (n = 8).
4.1. Comparison of Ph-negative myeloproliferative
neoplasms stratified by the JAK2V617F mutation
Total cohort in our study included 170 ET, 135 PV, and 105
PMF patients (410 Ph-negative MPNs). Mean duration of
follow-up was 76.7 months (SD 62.1). The mean age of the
total cohort (50% females) at diagnosis and at time of data
collection was 53.3 (SD 14.9) and 60.3 years (SD 14.8),
respectively.
Clinical and laboratory characteristics of Ph-negative
MPN patients stratified by the JAK2V617F mutation are
outlined in Table 1.
Sex at the time of data collection showed no difference
between JAK2V617F-positive and -negative Ph-negative
MPN subgroups. There was a trend towards older age at
diagnosis in JAK2V617F-mutated MPN patients compared
to JAK2V617F-unmutated patients (mean 54.34 [15] and
51.39 [14.79], respectively; p = 0.052). Ph-negative MPN
patients with JAK2V617F mutation presented with higher
leukocyte count, higher Hgb and Hct levels and lower
platelet count at diagnosis compared to patients without
the mutation (p = 0.001, p = 0.005, p = 0.001, and p = 0.003,
respectively). LDH levels were similar for the groups.
There was a trend towards greater spleen size
in JAK2V617-positive MPN patients compared to
JAK2V617F-negative patients (mean 148.33 mm [43.08]
and 137.74 mm [31.87], respectively; p = 0.056).
JAK2V617F positive MPN patients showed a trend
towards higher prevalence of risk factors for cardiovascular

Table 1. Clinical and laboratory characteristics of patients with Ph-negative myeloproliferative neoplasms according to the
JAK2V617F mutation (n = 410).
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Ph-negative myeloproliferative neoplasms

JAK2V617F-mutated
n (%)

JAK2V617F- unmutated
n (%)

p value

Hct at diagnosis (%)

43.46 [9.66]

39.75 [9.42]

0.001

Platelet count at diagnosis (mm3)

639.420 [351.700]

799.320 [521.100]

0.003

LDH at diagnosis (U/L)

465.9 [315.3]

438.1 [260.3]

0.876

Spleen size at diagnosis (mm)

148.33 [43.08]

137.74 [31.87]

0.056

Follow-up duration (months)

82.04 [63.07]

74.67 [61.73]

0.224

Number of patients

298

112

-

Risk factors for cardiovascular diseases

223 (74.8%)

73 (65.2%)

0.052

Phlebotomy

105 (35.2%)

23 (20.5%)

0.004

Bleeding

43 (14.4%)

9 (8%)

0.083

Thrombosis

100 (33.6%)

29 (25.9%)

0.059

Leukemic Transformation

9 (3%)

3 (2.7%)

0.855

Death

51 (17.1%)

12 (10.7%)

0.11
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diseases and thrombosis compared to JAK2V617F-negative
patients (74.8% and 65.2%, respectively; p = 0.052 and
33.6% and 25.9%, respectively; p = 0.059). The frequency
of phlebotomy in JAK2V617F-mutated MPN patients
was higher than JAK2V617F-unmutated patients (35.2%
and 20.5%, respectively; p = 0.004). JAK2V617F-mutated
MPN showed a higher yet not statistically significant rate
of bleeding events than the JAK2V617F-negative group
(14.4% and 8%, respectively; p = 0.083).
Duration of follow-up in patients with and without
JAK2V617F mutation were 82.04 months (SD 63.07) and
74.67 months (SD 61.73), respectively (p = 0.224). The
rate of death and leukemic transformation did not differ
between the two groups.
4.1.1. Survival curves: Kaplan–Meier survival curves in
patients with Ph-negative myeloproliferative neoplasms
according to JAK2V617F mutation
JAK2V617F mutation was tested in survival analysis for
influence on OS and LFS in patients diagnosed with Phnegative MPNs. Kaplan–Meier plots revealed similar OS
for JAK2617F mutated (n = 298) and JAK2617F-unmutated
(n = 112) patients (mean 234 months; 95% CI: 204–264
and 230 months; 95% CI: 199–260, respectively; p = 0.199)
(Figure 1a). Moreover, comparison across patients with
JAK2V617F mutation-positive and JAK2V617F mutationnegative patients showed no significant difference in LFS
(mean 338 months; 95% CI: 328–349 and 275 months;
95% CI: 257–293, respectively; p = 0.748) (Figure 1b).
4.2. Comparison of essential thrombocythemia patients
according to JAK2V617F mutation
One hundred and eight of 170 ET patients harbored
JAK2V617F mutation (63.5). The mean duration of followup was 87 months (SD 67.8). The mean age of ET patients
(60% females) at diagnosis and at time of data collection
a

was 50.2 (SD 15.4) and 57.9 years (SD 15.6), respectively.
Clinical and laboratory features of ET patients
according to JAK2V617F mutation are summarized in
Table 2.
JAK2V617F-mutated ET patients showed a higher
yet not statistically significant rate of females compared
to JAK2V617F-unmutated patients (64.8% and 51.6%,
respectively; p = 0.091). Age at diagnosis and age at time of
data collection were similar between JAK2V617F-mutated
and -unmutated ET patients. JAK2V617F-mutated ET
patients showed higher Hgb and Hct levels and lower
platelet count at diagnosis compared to JAK2V617Funmutated patients (p = 0.001, p = 0.001, and p = 0.001,
respectively). Leukocyte count, LDH level, and spleen size
at diagnosis were not different between the groups.
Prevalence of risk factors for cardiovascular diseases,
rate of bleeding and thrombosis were similar between the
two groups.
Duration of follow-up for JAK2V617F-mutated and
-unmutated patients was 85.23 months (SD 67.87) and
90.1 months (SD 68.18), respectively (p = 0.560). There was
a trend towards higher rate of leukemic transformation
in the JAK2V617F-unmutated group compared to the
JAK2V617F-mutated group (3.2% and 0, respectively; p =
0.061). The rate of death showed no difference between the
groups.
4.2.1. Survival curves: Kaplan–Meier plots in patients
with essential thrombocythemia according to
JAK2V617F mutation
JAK2V617F mutation was tested in survival analysis
for influence on OS in patients diagnosed with ET.
JAK2V617F-mutated and unmutated ET patients showed
no significant difference in OS (mean 237 months; 95% CI:
208–267 and 251 months; 95% CI:221–282, respectively; p
= 0.879) (Figure 2).
b
Ph-negative myeloproliferative neoplasms

Ph-negative myeloproliferative neoplasms
1.0

1.0

JAK2V617F mutation-negative (n=112)
JAK2V617F mutation-positive (n=298)

Probabalitiy of leukemia-free survival

JAK2V617F mutation-negative (n=112)
JAK2V617F mutation-positive (n=298)

Cumulative survival

0.8

0.6

0.4

0.2

0.8

0.6

0.4

0.2

0.0

0.0
0

100

200

Overall Survival (months)

300

400

0

100

200

300

400

Leukemia-free survival (months)

Figure 1. Survival outcomes and Leukemia-free survival in Ph-negative myeloproliferative neoplasms (n = 410). a. Survival analysis of
patients diagnosed with Ph-negative myeloproliferative neoplasms according to JAK2V617F mutation. OS was similar for JAK2V617F
mutation positive and JAK2V617F mutation negative patients (p = 0.199). b. Kaplan–Meier plot showing LFS in patients diagnosed with
Ph-negative myeloproliferative neoplasms according to JAK2V617F mutation. LFS showed no difference with respect to JAK2V617F
mutation (p = 0.748).
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Table 2. Clinical and laboratory characteristics of patients with essential thrombocythemia patients according to
JAK2V617F mutation (n = 170).
ET

JAK2V617F-mutated
(mean [SD])

JAK2V617F-unmutated
(mean [SD])

p value

Number of patients

108

62

-

Females (%)

70 (64.8%)

32 (51.6%)

0.091

Age at diagnosis

49.74[15.86]

51.15[14.87]

0.506

Age at time of data collection

57.39[16.12]

58.87[14.87]

0.554

Leukocyte at diagnosis (mm3)

10.344[3751]

10.119 [3288]

0.819

Hgb at diagnosis (g/dL)

13.86 [1.56]

12.55 [1.96]

0.001

Hct at diagnosis (%)

41.95 [4.90]

37.59 [5.52]

0.001

Platelet count at diagnosis (mm )

860.810 [310.900]

1.057.950 [465.300]

0.001

LDH at diagnosis (U/L)

359.2 [170.4]

400.8 [172.9]

0.078

Spleen size at diagnosis (mm)

132.49 [28.8]

128.51 [20.72]

0.495

Risk factors for cardiovascular diseases

38 (61.3%)

74 (68.5%)

0.339

Bleeding

12 (11.1%)

5 (8.1%)

0.524

Thrombosis

36 (33.3%)

20 (32.3%)

0.886

Leukemic transformation

0

2 (3.2%)

0.061

Death

5 (8.1%)

13 (12%)

0.419

3

ET

1.0

JAK2V617F mutation-negative (n=62)
JAK2V617F mutation-positive (n=108)

Cumulative survival

0.8

0.6

0.4

0.2

0.0
0

50

100

150

200

250

300

Overall Survival (months)

Figure 2. Kaplan–Meier estimate of survival in ET patients according to JAK2V617F mutation. OS was similar for JAK2V617F mutation
positive and negative ET patients (p = 0.879)

4.3. Comparison of polycythemia vera patients according
to JAK2V617F mutation
Among the 135 patients diagnosed with PV, the frequency
of JAK2V617F mutation was 81.5% (n = 110). The mean
duration of follow-up was 70.4 months (SD 56.4). The
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mean age of PV patients (65.2% males) at diagnosis and at
time of data collection was 55.01 (SD 14.1) and 61.2 years
(SD 14.1), respectively.
Clinical and laboratory characteristics of PV patients
stratified by JAK2V617F mutation are outlined in Table 3.
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The rate of female PV patients was higher in the
JAK2V617F-positive group compared to the JAK2V617Fnegative group (40% and 12%, respectively; p = 0.008).
Compared to JAK2V617F mutation-negative PV patients,
JAK2V617F mutation-positive PV patients showed a
higher yet not statistically significantmean age at diagnosis
and age at time of data collection (56.04 (SD 13.90) and
50.52 (SD 14.15), respectively; p = 0.082 and 62.25 (SD
13.91) and56.68 (SD 14.51), respectively; p = 0.071).
JAK2V617F-mutated PV patients showed lower Hgb
levels, higher leukocyte and platelet counts at diagnosis
compared to JAK2V617F-unmutated patients (p = 0.018;
p = 0.001 and p = 0.001, respectively). Hct and LDH levels
and spleen size at diagnosis were not different between the
groups. JAK2V617F-mutated PV patients showed higher
prevalence of thrombosis compared to JAK2V617Funmutated patients (42.7% and 20%, respectively; p =
0.035)
Prevalence of risk factors for cardiovascular diseases,
rates of phlebotomy, and bleeding were similar between
the two groups.
Duration of follow-up in patients with and without
JAK2V617F mutation were 70.81 months (SD 56.76)
and 68.7 months (SD 55.86), respectively (p = 0.883). At
the end of data collection period, the rates of death and
leukemic transformation did not differ between the two
groups.
4.3.1. Survival curves: Kaplan–Meier plots in patients
with polycythemia vera according to JAK2V617F
mutation
In PV patients, JAK2V617F mutation was tested in
univariate survival analysis for influence on OS. OS did
not differ between JAK2V617F-mutated and JAK2V617Funmutated PV patients (mean 217 months; 95% CI: 196–
238 and 215 months; 95% CI: 213–217, respectively; p =
0.887) (Figure 3).
4.4. Comparison of primary myelofibrosis patients
according to JAK2V617F mutation (n = 105)
For the 105 PMF patients included in the study, the
frequency of JAK2V617F mutation was 76.2% (n = 80).
Mean duration of follow-up was 68 months (SD 57.4). The
mean age of PMF patients (46.7% males) at diagnosis and
at time of data collection was 56.93 (SD 14.37) and 63.09
years (SD 13.64), respectively. According to DIPSS-plus
risk stratification, PMF patients were divided into low,
intermediate-1, intermediate-2 and high risk groups (19%
(n = 20), 37% (n = 39), 33% (n = 35) and 11% (n = 11).
Clinical and laboratory characteristics of PMF patients
according to JAK2V617F mutation are summarized in
Table 4.
The rate of females was higher in the JAK2V617Funmutated PMF patients compared to the JAK2V617Fmutated patients (84% and 43.8%, respectively; p = 0.001).

Mean age at diagnosis and age at time of data collection
were not different between PMF patients with and without
JAK2V617F mutation.
JAK2V617F-mutated PMF patients showed higher
leukocyte count at diagnosis compared to JAK2V617Funmutated PMF patients (p = 0.019). In JAK2V617Fmutated PMF patients, a trend towards higher Hgb level
at diagnosis was observed compared to JAK2V617Funmutated PMF patients (p = 0.056). Hct and LDH levels
and platelet count at diagnosis did not differ between
the groups. JAK2V617F- mutated PMF patients showed
greater spleen size compared to JAK2V617F-unmutated
patients (mean 193 mm (SD 48) and 171 mm (SD 40),
respectively; p = 0.042)
JAK2V617F-mutated PMF patients showed a higher
yet not statistically significant prevalence for risk of
cardiovascular diseases and rate of bleeding compared to
patients without mutation (71.3% and 52%, respectively;
p = 0.075 and 23.8% and8%, respectively; p = 0.086). The
frequency of thrombosis was similar between JAK2V617Fmutated and -unmutated patients.
Duration of follow-up in patients with and without
JAK2V617F mutation were 65.74 months (SD 58.19) and
75.36 months (SD 55.32), respectively (p = 0.304). At
the end of data collection period, the rate of death and
leukemic transformation were similar between the two
groups.
4.4.1. Survival curves: Kaplan-Meier plots in patients
with Primary myelofibrosis according to JAK2V617F
mutation and DIPSS-plus risk stratification
For PMF patients, JAK2V617F mutation and DIPSSplus risk stratification were tested in univariate survival
analysis for influence on OS and LFS. JAK2V617F positive
(n = 80) and JAK2V617F-negative PMF (n = 25) patients
showed no significant difference in OS (mean 162 months;
95% CI: 114–210 and 161 months; 95% CI: 110–212,
respectively; p = 0.134) (Figure 4a). Comparison across
DIPSS-plus high risk patients (n = 11), intermediate-2 (n
= 35), intermediate-1 (n = 39), and low risk patients (n =
20) demonstrated that DIPSS-plus high risk patients lived
shorter compared to the other risk groups (p = 0.001)
(mean 59 months; 95% CI: 14–104, 104 months; 95% CI:
75–133, 222 months; 95% CI: 163–281 and 216 months;
95% CI: 177–254 respectively; p = 0.001) (Figure 4b).
LFS was not different between JAK2V617F-mutated and
-unmutated PMF patients (mean 309 months; 95% CI:
274–343 and 239 months; 95% CI: 221–258, respectively;
p = 0.354) (Figure 4c). LFS was shorter in DIPSS-plus high
risk PMF patients compared to the other risk groups (mean
109 months; 95% CI: 73–145 in high risk, 167 months; 95%
CI: 146–188 in intermediate-2, 327 months; 95% CI: 289–
365 in intermediate-1 and 236 months; 95% CI: 213–260 in
low risk, respectively; p = 0.005) (Figure 4d).

155

ŞAHİN et al. / Turk J Med Sci
Table 3. Clinical and laboratory characteristics of patients with Polycythemia vera patients according to JAK2V617F
mutation (n = 135).
PV

JAK2V617F-mutated
(mean [SD])

JAK2V617F-unmutated
(mean [SD])

p value

Number of patients

110

25

-

Females (%)

44 (40%)

3 (12%)

0.008

Age at diagnosis

56.04[13.90]

50.52[14.15]

0.082

Age at time of data collection

62.25[13.91]

56.68 [14.51]

0.071

Leukocyte at diagnosis (mm3)

12.970[5590]

8.538 [2797]

0.001

Hgb at diagnosis (g/dL)

16.59 [2.60]

17.78 [1.94]

0.018

51.2 [7.67]

0.622

Hct at diagnosis (%)
Platelet count at diagnosis (mm )

557.090 [268.200]

LDH at diagnosis (U/L)

375 [220]

52.33 [6.12]
382.330
[355.900]
294 [110]

Spleen size at diagnosis (mm)

131 [24]

127 [21]

0.351

Follow-up duration (months)

70.81 [56.76]

68.7 [55.86]

0.883

Risk factors for cardiovascular diseases

92 (83.6%)

22 (88%)

0.764

Phlebotomy

90 (81.8%)

20 (80%)

0.782

Bleeding

12 (10.9%)

2 (8%)

0.499

Thrombosis

47 (42.7%)

5 (20%)

0.035

Leukemic transformation

2 (1.8%)

0

0.499

Death

9 (8.2%)

1 (4%)

0.473

3

0.001
0.202

PV

1.0

JAK2V617F mutation-negative (n=25)
JAK2V617F mutation-positive (n=110)

Cumulative survival

0.8

0.6

0.4

0.2

0.0
0
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Figure 3. Overall survival comparison among 135 patients with PV divided by JAK2V617F mutation. OS was similar between
JAK2V617F mutation-positive and JAK2V617F mutation-negative PV (p = 0.887).
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Table 4. Clinical and laboratory characteristics of patients with Primary myelofibrosis patients according to JAK2V617F
mutation (n = 105).
PMF

JAK2V617F-mutated
(mean [SD])

JAK2V617F-unmutated
(mean [SD])

p value

Number of patients

80

25

-

Females (%)

35 (43.8%)

21 (84%)

0.001

Age at diagnosis

58.2 [13.80]

52.88 [15.68]

0.107

Age at time of data collection

64.05 [13.17]

60 [14.91]

0.197

Leukocyte at diagnosis (mm3)

16.180 [13.865]

10.377 [7771]

0.019

Hgb at diagnosis (g/dL)

11.55 [2.70]

10.54 [2.59]

0.056

Hct at diagnosis (%)

34.85 [8.7]

32.53 [8.01]

0.162

Platelet count at diagnosis (mm )

453.760 [351.700]

574.900 [415.300]

0.224

LDH at diagnosis (U/L)

735 [408]

674 [376]

0.606

Spleen size at diagnosis (mm)

193 [48]

171 [40]

0.042

Follow-up duration (months)

65.74 [58.19]

75.36 [55.32]

0.304

Risk factors for cardiovascular diseases

57 (71.3%)

13 (52%)

0.075

Bleeding

19 (23.8%)

2 (8%)

0.086

Thrombosis

17 (21.3%)

4 (16%)

0.567

Leukemic Transformation

7 (8.7%)

1 (4%)

0.437

Death

29 (36.25%)

6 (24%)

0.259

Risk factors for cardiovascular diseases

57 (71.3%)

13 (52%)

0.075

3

5. Discussion
Our study included a large number of patients diagnosed
with Ph-negative MPNs (n = 410) with a long duration of
follow-up- 170 ET patients with a mean follow-up duration
of 87 months (SD 67.8), 135 PV patients with a mean
follow-up duration of 70.4 months (SD 56.4) and 105 PMF
patients with a mean follow-up duration of 68 months
(SD 57.4). In a 2021 update of Ph-negative MPNs, it was
reported that JAK2V617F mutation was displayed in 96%,
55%, and 65% of PV, ET, and PMF patients, respectively
[2]. However, in a systematic review, the frequency of
the JAK2V617F mutation in Ph-negative MPNs showed
marked variation with incidence rates ranging between
46.7% and 100% in PV, 31.3% and 72.1% in ET, and 25%–
85.7% in PMF [23]. Differences in the literature may be
attributed to the heterogeneous diagnostic techniques
[23]. In our study, we used a semiquantitative assay -JAK2
MutaScreen- with a sensitivity of 2% in 228 patients and
real-time PCR assay using FFET probes and melting curve
analysis with a sensitivity of 10% in the remaining 182
patients [21,22]. In our study, the frequency of JAK2V617F
mutation in PV was higher compared to ET and PMF
patients (81.5%, 63.5% and 76.2%, respectively).
Several studies have reported the comparison
of ET patients according to JAK2V617F mutation
[4,5,9,12,13,24-36]. In a study including 218 consecutive

ET patients, the presence of JAK2V617F mutation retained
a negative prognostic impact for predicting thrombosis
[4]. In another study including 53 ET patients, JAK2V617F
mutation showed significant correlation with higher
leukocyte counts, higher Hgb levels and thrombotic events
while age, sex, platelet count, frequency of splenomegaly,
and bleeding events did not differ between the JAK2617Fpositive and JAK2V617F-negative ET patients [24]. In a
study including 102 ET patients, females were reported
to more frequently harbor the JAK2V617F mutation and
JAK2V617F mutated patients were found to be older
and had higher leucocyte counts [25]. Another study
including 150 ET patients showed that JAKV617F mutated
subgroup was associated with advanced age, higher Hgb
level and leukocyte counts [12]. In the same study, sex,
platelet count, palpable splenomegaly, thrombosis, and
hemorhage at presentation and at follow-up showed no
difference according to JAK2V61F mutation [12]. In a
metaanalysis, however, it was reported that JAK2V617F
increased the risk of arterial and venous thrombosis in
ET [5]. Another metaanalysis including 325 published
articles also supported that JAK2V617F positive ET
was associated with increasing odds of thrombosis [26].
In a comprehensive study including 395 ET patients,
JAK2V617F-positive patients had significantly higher
Hgb level and leukocyte counts but lower platelet counts
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Figure 4. Survival outcomes and leukemia-free survival in primary myelofibrosis patients (n = 105). a. Kaplan–Meier plot showing OS
in PMF patients according to JAK2V617F mutation. OS was similar between JAK2V617F-positive and JAK2V617F-negative patients
(p = 0.134). b. Survival analysis of patients diagnosed with PMF according to DIPSS-plus risk stratification. OS was shorter in DIPSSplus high risk PMF patients with respect to other risk groups (p = 0.001). c. LFS comparison between 80 JAK2V617F-mutated and 25
JAK2V617F-unmutated patients with PMF. LFS was similar between JAK2V617F-mutated and -unmutated PMF patients (mean 309
months; 95% CI: 274–343 and 239 months; 95% CI:221-258, respectively; p = 0.354). d. LFS data of PMF patients according to DIPSSplus risk stratification. PMF patients with DIPSS-plus high risk group had significantly shorter LFS compared to other risk groups (p =
0.005).

compared to JAK2V617F-negative patients [27]. In a
study including 275 ET patients, JAK2V617F-positive
patients were older and displayed higher Hgb and Hct
levels and higher incidence of splenomegaly, but lower
platelet count and lower incidence of hemorrhagic events
compared with patients without the mutation while sex,
leukocyte count, incidence of thrombosis was comparable
between the groups [30]. In a study, JAK2V617Fpositive ET patients displayed higher Hgb and Hct levels
whereas leukocyte and platelet counts, sex, age, disease
duration did not differ between JAK2V617F-positive and
negative ET patients [31]. In another study including 92
ET patients, significantly higher values were also found
for Hgb level and leukocyte count in the JAK2V617F
mutation positive group yet platelet count, LDH level, age,
sex and thrombosis did not differ between JAK2V617Fpositive and negative patients [32]. In another study, it
was demonstrated that JAK2V617F-positive ET patients
showed advanced age, higher leukocyte count and
Hgb level whereas platelet count was similar between
JAK2V617F-positive and -negative groups [33]. In a study
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including 111 ET patients, the presence of JAK2V617F
mutation correlated with older age, higher levels of Hgb
and Htc levels, greater probability of having splenomegaly
at diagnosis while mutation positive and negative groups
showed no difference with respect to sex, probability of
hemorrhagic events, leukocyte count, and LDH levels
[13]. In a very large ET series including 806 patients,
JAK2V617F-positive patients had significantly increased
Hgb level, neutrophil count, more venous thrombosis
compared to JAK2V617F-negative ET patients [36]. In a
previous study including 107 ET patients, JAK2V617Fpositive patients presented with higher Hgb and Hct levels
and lower platelet count and more prevalent splenomegaly
while age, sex, leukocyte count, LDH level, spleen size, rate
of bleeding complications and thrombosis and duration of
follow-up did not differ between the groups [9]. In our
study, JAK2V617F-positive ET patients displayed higher
Hgb and Hct levels and lower platelet count at diagnosis
compared to JAK2V617F-negative patients while no
differences were observed between the groups regarding
age, sex, leukocyte count, LDH level, spleen size at
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diagnosis, duration of follow-up, prevalence of risk factors
for cardiovascular diseases, rate of bleeding and thrombosis.
In our study, JAK2V617F-positive ET patients showed
higher Hgb and Hct levels in line with previous studies yet
as opposed to the study by Wong et al. [9, 12, 13, 24, 25,
27-36]. In agreement with some previous studies but in
contrast to the study by Pósfai et al., in which JAK2V617F
mutation was associated with increased platelet count and
in contrast to some studies in which the platelet count was
reported not to differ between JAK2V617F-positive and
negative patients, our study demonstrated that the platelet
count was lower in in JAK2V617F-positive ET patients
patients [9,12,24,25,27-34]. Contrary to most previous
studies showing association between the JAK2V617F
mutation and higher leukocyte count yet confirming some
of the previous reports, our JAK2V617F-positive and
negative ET patients showed no difference with respect
to leukocyte counts [9,12,13,24,25,27-36]. Confirming
previous data, we found no difference in LDH levels
between JAK2V61F-positive and -negative ET patients
[9,29,32,34]. Some previous studies showed an association
between JAK2V617F mutation and older age in ET patients
while others found no association [9,12,13,24,25,29-34].
In line with the aferomentioned several studies, age was
similar between our JAK2V617F-positive and -negative ET
patients [9,24,29,31,32,34]. Consistent with most previous
observations but contrary to the study by Wong GC et al.,
sex did not differ according to JAK2V617F mutation in
our ET patients [9,12,13,24,25,29,30,32,34]. Contrary to
previous some reports but in line with other observations,
we found no association between JAK2V617F mutation
and spleen size [9,12,13,24,29,30,34]. In line with previous
studies, the duration of follow-up between our ET patients
with and without the JAK2V617F mutation was similar
[9,12,25,31]. Consistent with previous data yet contrary to
the observation by Palandri et al., we found no difference
in the rate of bleeding between JAK2V617F-positive
and JAK2V617F-negative patients [9,12,13,24,29,30].
Consistent with previous observations but contrary to
some others, the rate of thrombosis was similar between
our JAK2V617F-positive and -negative ET patients
[4,5,9,12,24,26,28-30,32,34,36]. Finally, similar to most
of the aferomentioned studies, our ET patients had some
hematological features resembling PV with significantly
increased Hgb and Hct levels yet contrary to some of the
previous studies, our ET patients did not promote a PV
phenotype in terms of vascular events [4,5,12,13,24,2636].
Because ~95% of PV patients harbor JAK2V617F
mutations, limited studies have previously compared
JAK2V617F-positive and JAK2V617F-negative PV
patients [6,7,13,14,32,34,37-39]. In one study including
108 PV patients, patients with JAK2V617F mutation had

higher platelet, leukocyte counts, and LDH levels and were
older compared to JAK2V617F-unmutated patients while
the JAK2V617F-mutated and -unmutated PV patients
showed no difference for Hgb, sex, and thrombosis [32].
In a study including 80 PV patients, PV patients carrying
the JAK2V617F mutation had higher leukocyte and
platelet counts and were more prone to have splenomegaly
compared to patients without the mutation [34]. In the same
study, median age, sex, Hgb, and LDH levels, frequency of
thrombosis did not differ between JAK2V617F-positive
and JAK2V617F-negative PV patients [34]. Vannucchi
et al. reported that in PV patients, JAK2V617F mutation
clusters with older age, higher Hgb level, leukocytosis,
and lower platelet count [37]. In a study including 92 PV
patients, JAK2V617F-mutated patients were associated
with splenomegaly and they had higher leukocyte
and platelet counts and showed a significant increase
in LDH levels compared to JAK2V617F-unmutated
patients [14]. In the same study, the rate of males was
higher in JAK2V617F-negative PV patients compared to
JAK2V617F-positive patients while Hgb level did not differ
between patients with and without the mutation [14]. In
a study including 83 PV patients, leukocyte and platelet
counts and Hct level were similar between JAK2V617Fmutated and -unmutated patients [39]. In a series of 43
PV patients, age, sex, presence of splenomegaly and
thrombosis, Hgb and Hct levels, platelet count, and LDH
level were not different between JAK2V617F-mutated and
unmutated patients while -mutated patients had higher
leukocyte count and longer duration of follow-up [13]. In
our study including 135 PV patients, the rate of females was
higher in JAK2V617F-positive patients and JAK2V617Fpositive patients showed lower Hgb level, higher leukocyte
and platelet counts at diagnosis and a higher prevalence
of thrombosis while no differences were observed for
duration of follow-up, prevalence of cardiovascular risk
factors, rates of phlebotomy and bleeding, Hct, and LDH
levels and spleen size at diagnosis between the groups.
Moreover, our JAK2V617F-positive PV patients displayed
a higher yet not statistically significant mean age at
diagnosis and age at time of data collection compared to
JAK2V617F-negative patients. In our study, PV patients
with JAK2V617F mutation displayed lower Hgb level
compared to JAK2V617F-unmutated PV patients in
contrast with some studies showing correlation between
JAK2V617F mutation and higher Hgb level and other
studies showing no correlation between JAK2V617F
mutation and Hgb level [13,14,32,34,37,38]. In line with
previous observations, our JAK2V617F-mutated and
-unmutated PV patients showed similar Hct levels [13,39].
Consistent with previous reports yet in contrast to the study
by Ibrahim et al., our JAK2V617F-mutated PV patients
displayed higher leukocyte counts compared to patients
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without the mutation [16,13,14,32,34,37-39]. In our study,
JAK2V617F-mutated PV patients showed higher platelet
counts in agreement with most of the previous data yet
in contrast with some studies [6,7,13,14,32,34,37,39].
Confirming some previous studies but at variance
with some others, we found no correlation between
JAK2V617F mutation and LDH level [7,13,14,32,34]. In
line with some studies yet opposed to the others showing
correlation between JAK2V617F mutation and older age,
our PV patients showed no difference for age with respect
to the presence of JAK2V617F mutation [13,32,34,37].
In contrast with most of the previous studies yet in line
with the study by Soliman et al., the rate of female patients
was higher in our PV patients with JAK2V617F mutation
[13,14,32,34]. In our PV patients, spleen size was similar
between JAK2V617F-mutated and -unmutated patients as
opposed to most of the studies yet in line with the study by
Speletas M et al. [7,13,14,34]. In our PV patients, duration
of follow-up was similar between JAK2V617F-mutated
and -unmutated patients as opposed to the finding by
Speletas et al [13]. In our study, prevalance of thrombosis
was higher in JAK2V617F-mutated PV patients compared
to JAK2V617F-unmutated patients as opposed to the
previous data [13,32,34]. To our knowledge, there is no
previous data regarding the prevalence of risk factors for
cardiovascular diseases, rates of phlebotomy and bleeding
in PV patients according to JAK2V617F mutation. In our
study, we observed no correlation with the aforementioned
parameters and JAK2V617F mutation. Reported data
regarding the correlation of JAK2V617F mutation with
advanced age, decreased platelet counts, thrombotic risk,
splenomegaly have yielded contradictory results [40]. In
our large number of PV patients, we demonstrated that the
presence of the JAK2V617F mutation promoted a distinct
phenotype characterized by female predominance, lower
Hgb level, higher leukocyte and platelet counts and higher
prevalence of thrombosis.
Several studies have investigated the clinical correlations
of JAK2V617F mutation in patients with PMF [8,9,15,17,4144]. In a study including 152 PMF patients, JAK2V617Fmutated patients had higher leukocye count compared
to JAK2V617F-unmutated patients while age, sex, Hgb
level, LDH level, platelet count and spleen size were not
different between patients with and without the mutation
[15]. In a series of 117 PMF patients from a single center,
Tefferi et al. reported no significant impact of the presence
of JAK2V617F mutation on sex, Hgb level, leukocyte
count, platelet count, LDH level, spleen size, bleeding
history, but the presence of the JAK2V617F mutation
was found to be associated with older age and history
of thrombosis [8]. In another study including 304 PMF
patients, the presence of JAKV617F mutation contributed
to laboratory and clinical abnormalities including higher
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Hgb level and leukocyte count and development of
marked splenomegaly [17]. In another study including
199 PMF patients, the presence of JAK2V617F mutation
showed no correlation with sex, Hgb level, platelet count,
and incidence of thrombosis while JAK2V617F-mutated
patients were significantly of older age and showed a trend
towards higher leukocyte count [41]. In a study including
186 PMF patients, JAK2V617F-mutated patients had
significantly higher Hgb level, leukocyte count and platelet
count compared to JAK2V617F-unmutated patients [42].
In the aferomentioned study, there was no impact of the
mutated genotype on age, sex, LDH level, duration of
follow-up and the presence of a palpable spleen greater
than 15 cm [42]. In a series of 77 Turkish PMF patients,
it was demonstrated that JAK2V617F-mutated patients
presented with significantly higher leukocyte count,
Hb and Hct levels and included a lower rate of female
patients compared to JAK2V617F-unmutated patients
while no significant difference was reported for age,
platelet count, LDH level, spleen size, duration of followup and prevalance of thrombosis [9]. In the present study
including 105 PMF patients, JAK2V617F-mutated PMF
patients included a lower rate of female patients and they
displayed higher leukocyte count, greater spleen size, a
trend towards higher Hgb level. In our study, age, Hct,
and LDH levels, platelet count, duration of follow-up and
prevalence of thrombosis were found to be similar between
JAK2V617F-mutated and -unmutated patients. Moreover,
our JAK2V617F-mutated PMF patients showed a higher
yet not statistically significant prevalence of cardiovascular
risk factors and rate of bleeding compared to -unmutated
patients. In our study, JAK2V617F-mutated PMF displayed
a trend towards higher Hgb level in line with some reports
yet as opposed to other data [8,9,15,17,41-44]. In contrast
with one previous study, our JAK2V617F-mutated and
-unmutated PMF patients showed no difference in Hct
levels [9]. In agreement with most studies yet opposed to
some others, leukocyte count in our JAK2V617F-mutated
PMF patients was higher [8,9,15,17, 41-43]. Confirming
most previous observations but contrary to some others,
we found no correlation between JAK2V617F mutation
and platelet count [8,9,15,17,41-43]. In accordance with
previous observations but in contrast with the study by
Helbig et al., our JAK2V617F-mutated and -unmutated
PMF patients showed no difference in LDH level
[8,9,15,41,42]. In line with some previous studies yet as
opposed to some others, we did not observe any impact
of JAK2V617F mutation on age [8,9,15,17,41-43]. In
contrast with some reports yet confirming the findings
of a previous study, JAK2V617F-mutated PMF patients
included a lower rate of females [8,9,15,17,41]. Contrary to
previous studies yet in line with the report by Barosi et al.,
our JAK2V617F-mutated PMF patients displayed greater
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spleen size compared to JAK2V617F-unmutated patients
[8,9,15,17,41-43]. Consistent with previous reports,
duration of follow-up of our JAK2V617F-mutated and
-unmutated PMF patients was similar [9,41]. In agreement
with previous studies but in contrary to the study by
Tefferi et al., we found no difference in the prevalance of
thrombosis [8,9,17]. Rate of bleeding was similar between
our PMF patients with and without the JAK2V617F
mutation, consistent with the observation by Tefferi et al.
[8]. As a whole, we found a significant association between
the presence of JAK2V617F mutation and a more marked
myeloproliferative phenotype in PMF patients.
Several studies have reported the comparison of an
entire cohort of Ph-negative MPNs according to the
JAK2V617F mutation [10, 11, 13, 45, 46]. In a study
including a total cohort of 186 patients diagnosed with
MPN, individuals harboring the JAK2V617F mutation
were reported to have higher risk for VTE but not for
arterial thrombosis or bleeding complications [10]. In
another study including 166 MPN patients, the presence of
the JAK2V617F mutation correlated with older age, higher
levels of Hct and Hgb while sex, platelet count, LDH level,
rate of thrombosis and bleeding complications, follow-up
duration did not differ between patients with and without
the mutation [13]. In a series of 412 MPN patients, there
was a correlation between the JAK2V617F mutation and
advanced age, higher leukocyte count and Hgb level and
presence of thrombosis [11]. In a study including 88 MPN
patients, the risk of thrombosis and bleeding were not
affected by the presence of the JAK2V617F mutation [45].
In a series of 148 MPN patients (including PV and ET),
JAK2V617F-mutated patients displayed older age, higher
Hgb level and leukocyte count, lower platelet count and
more prevelant splenomegaly compared to JAK2V617Funmutated patients while sex was not different between
the groups [46]. In our study including 410 MPN patients
(170 ET, 135 PV, 105 PMF), JAK2V617F-mutated
patients displayed a trend towards older age at diagnosis,
higher leukocyte count, higher Hgb and Hct levels and
lower platelet count, a trend towards greater spleen size,
higher frequency of phlebotomy, a trend towards higher
prevalence of cardiovascular risk factors and higher rate of
thrombosis while sex, LDH level, rate of bleeding events,
duration of follow-up did not differ between patients with
and without the mutation. In our study, JAK2V617Fmutated MPN patients displayed higher Hgb level in
agreement with previous reports [11,13, 45, 46]. Moreover,
consistent with the report of Speletas et al., we found a
correlation between the JAK2V617F mutation and higher
Hct level [13]. Confirming previous data, JAK2V617Fmutated MPN patients showed higher leukocyte counts
compared to JAK2V617F-unmutated patients [11,45,46].
In accordance with the previous observation of Karkucak

et al. but in contrast to the study by Lieu et al., our
JAK2V67F-positive MPN patients had lower platelet
counts [45,46]. Consistent with the report of Speletas et
al., LDH level did not differ between our MPN patients
with and without JAK2V617F mutation [13]. In our
study, there was a trend towards older age in JAK2V617Fmutated MPN in line with previous reports yet as opposed
to the finding by Lieu et al. [11,13,45,46]. Confirming
previous reports, we found no sex difference in our MPN
patients according to the JAK2V617F mutation [13,45,46].
Consistent with previous reports showing association
between the JAK2V617F mutation and splenomegaly in
MPN, our JAK2V617F-mutated MPN patients also showed
a trend towards greater spleen size [45,46]. In line with
the report by Speletas et al. yet contrary to the report by
Lieu et al., duration of follow-up was similar between our
MPN patients with and without the JAK2V617F mutation
[13,45]. In line with a study including a large series of
MPN patients, which showed correlation between the
JAK2V617F mutation and thrombosis and with the study
by Borowczyk et al., which showed higher incidence of
VTE in patients with the JAK2V617F mutation, we found
a trend towards a higher prevalence of thrombosis in our
JAK2V617F-mutated MPN patients [10,11]. In contrast
with the aforementioned findings, some other previous
studies found no significant increased risk of thrombosis
in JAK2V617F-mutated patients [13,45]. Confirming
previous data, the rate of bleeding events was similar
between our MPN patients with and without JAK2V617F
mutation [10,13,45]. Consequently, in our MPN patients,
the presence of the JAK2V617F mutation promoted a PV
phenotype characterized by older age, higher leukocyte
count, higher Hgb and Hct levels, lower platelet count,
greater spleen size, thrombotic risk and higher rate of
phlebotomy.
There are several reports that have highlighted the
impact of JAK2V61F mutation on outcomes of PV,
ET, PMF and the entire cohort of Ph-negative MPN
patients [8, 9, 12-14,16, 17, 19, 30, 41, 43, 47, 48]. To our
knowledge, there is limited data regarding the outcome
of PV patients according to the JAK2V617F mutation.
In a study including 60 PV patients, the rate of leukemic
transformation showed no difference according to the
presence of the JAK2V617F mutation [47]. Similarly,
in our study which includes 135 PV patients, the rate
of leukemic transformation was not different between
JAK2V617F-positive and JAK2V617F-negative group
[47]. Moreover, death and OS were similar between our
JAKV617F-mutated and JAK2V617F-unmutated PV
patients. In a study including 107 ET patients, OS was
similar between JAK2V617F-positive and JAK2V617Fnegative patients [48]. In another study including 141 ET
patients, the 10-year OS was not different in patients with
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and without the JAK2V617F mutation. Moreover, in that
study, the rate of death and blastic transformation were not
different in patients with and without the mutation [16]. In
line with the aforementioned observation, another study
reported that no difference was observed in the rates of
death with respect to JAK2V617F mutational status in ET
patients [9]. In contrast with the previous data, another
study including 111 ET patients reported that patients
carrying the JAK2V617F mutation had a three-fold
higher probability of death compared to those without the
JAK2V617F mutation [13]. In a study including 150 ET
patients, the number of deaths was significantly higher in
JAK2V617F-mutated patients compared to JAK2V617Funmutated patients [12]. In the same study, multivariate
analysis did not show the presence of JAK2V617F
mutation as a significant predictor in ET patients for
OS [12]. On the contrary, in one study which evaluated
the correlation between the JAK2V617F mutation and
OS, it was demonstrated that JAK2V617F-mutated ET
patients had shorter OS [14]. In one study including
275 ET patients, the incidence of disease transformation
was not different between JAK2V617F-positive and
JAK2V617F-negative patients [30]. In our study, there was
a trend towards higher rate of leukemic transformation
in JAK2V617F-unmutated ET patients compared to
mutated patients while the rate of death was not different
between the groups. Moreover, JAK2V617F-mutated and
-unmutated ET patients showed no significant difference
in OS. In a previous study including 77 PMF patients, the
rates of leukemic transformation and death were similar
between the JAK2V617F-positive and -negative groups
[9]. In another study including PMF patients, the presence
of JAK2V617F mutation had no impact on OS and LFS
[48]. On the contrary, in a series of 152 PMF patients,
JAK2V617F-positive patients showed significantly worse
survival compared to JAK2V617F-negative patients [15].
In a series of 117 PMF patients, JAK2V617F mutation
showed no significant impact on either survival or leukemic
transformation [8]. In another study including 304 PMF
patients, JAK2V617F mutation was associated with
increased risk of death and leukemic transformation [17].
In a series of 199 PMF patients, JAK2V617F mutation had
no correlation with survival or leukemic transformation
[41]. In another study including 77 PMF patients, the
presence of JAK2V617F mutation showed no impact on
OS and the risk of leukemic transformation [43]. In our
series of 105 PMF patients, JAK2V617F-mutated and
-unmutated patients showed no significant difference for
the rate of death, leukemic transformation, OS, and LFS.
Studies about the impact of JAK2V61F mutation on OS
and the risk of leukemic transformation in ET and PMF
patients have yielded controversial results. In agreement
with previous data, our study demonstrated that DIPSS-
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plus high risk PMF patients had shorter survival compared
to the other risk groups [19]. Moreover, LFS was shorter in
DIPSS-plus high risk PMF patients compared to the other
risk groups. There is limited data regarding the outcome
of Ph-negative MPNs according to the JAK2V617F
mutation. In a series of 166 total MPN patients, the rate
of death was not different between JAK2V617F-positive
and JAK2V617F-negative patients [13]. In our series of
410 Ph-negative MPNs, the rate of death and leukemic
transformation, OS, and LFS were similar between
JAK2V617F-positive and JAK2V617F-negative subgroups.
In conclusion, our results imply that in a large series
of PV patients, JAK2V617F mutation is associated with
a higher rate of female patients, lower Hgb level, higher
leukocyte and platelet counts, and higher prevalence of
thrombosis. In a large series of ET patients, our findings
suggest that JAK2V617F mutation is associated with PVlike phenotype with higher Hgb and Hct levels and lower
platelet counts. Moreover, our JAK2V617F-negative ET
patients displayed a trend towards higher rate of leukemic
transformation. In PMF patients, our results point out
that JAK2V617F mutation is associated with a more
pronounced myeloproliferative phenotype with higher
leukocyte count, greater spleen size, a trend towards
higher Hgb level. Moreover, the rate of females was lower
in JAK2V617F-mutated PMF patients. In a total of very
large number of Ph-negative MPN patients, our findings
support that JAK2V617F mutation is associated with a
more aggressive phenotype witha trend towards older age
at diagnosis, higher leukocyte count, higher Hgb and Htc
levels and lower platelet count, a trend towards greater
spleen size, higher frequency of phlebotomy, a trend
towards a higher prevalence of cardiovascular risk factors
and thrombosis.
There are limitations that need to be acknowledged
and addressed regarding the present study. The first
limitation concerns the retrospective nature of the study.
Prospective studies are required to confirm the results
of the present study. The second limitation concerns the
characteristics of the study population of our PV patients.
The frequency of JAK2V617F mutation in our PV patients
is lower compared to the previous reports (81.5% and
96%, repectively). Since our study population is composed
of the patients of a reference center, to which many JAK
negative patients are referred and are diagnosed with
JAK2V617F-negative PV. Thus, the patient population can
be considered to have potential bias and our results cannot
be extended to the entire population of PV patients.
The impact of JAK2V617F mutation on clinical
phenotype in Ph-negative MPNs is still debated. As a
whole, our comprehensive study including large number
of Turkish MPN patients may indicate that JAK2V617F
mutation is accociated with distinct disease phenotypes of
PV, ET, PMF, and Ph-negative MPNs.
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